---
title: "MDR rule 20: Administering medicinal products by inhalation"
url: https://normiq.app/en/classification/mdr/rule-20
language: en
updated: 2026-11-15
---

# MDR rule 20: Administering medicinal products by inhalation

MDR · Annex VIII, Section 7.7 · SPECIAL RULES

Updated on November 15, 2026

## Official text

All invasive devices with respect to body orifices, other than surgically invasive devices, which are intended to administer medicinal products by inhalation are classified as class IIa, unless their mode of action has an essential impact on the efficacy and safety of the administered medicinal product or they are intended to treat life-threatening conditions, in which case they are classified as class IIb.

MDR, Annex VIII, Section 7.7, consolidated version of July 19, 2026.

Short link: [normiq.app/en/mdr/annexe/viii/20](https://normiq.app/en/mdr/annexe/viii/20)

## In plain words

A device invasive with respect to body orifices, other than surgically invasive, intended to administer medicinal products by inhalation is in class IIa, or class IIb if its mode of action has an essential impact on the efficacy and safety of the administered medicinal product or it is intended to treat life-threatening conditions.

Explanation written by Normiq; only the official text above is authoritative.

## Definitions the rule relies on

- MDR, Article 2, point 6

  ‘invasive device’ means any device which, in whole or in part, penetrates inside the body, either through a body orifice or through the surface of the body;

- MDR, Annex VIII, Section 2.1

  ‘Body orifice’ means any natural opening in the body, as well as the external surface of the eyeball, or any permanent artificial opening, such as a stoma.

- MDR, Annex VIII, Section 2.2

  ‘Surgically invasive device’ means:

  - an invasive device which penetrates inside the body through the surface of the body, including through mucous membranes of body orifices with the aid or in the context of a surgical operation; and
  - a device which produces penetration other than through a body orifice.

- MDR, Article 2, point 5

  ‘implantable device’ means any device, including those that are partially or wholly absorbed, which is intended:

  - to be totally introduced into the human body, or
  - to replace an epithelial surface or the surface of the eye,
  - by clinical intervention and which is intended to remain in place after the procedure.
  - Any device intended to be partially introduced into the human body by clinical intervention and intended to remain in place after the procedure for at least 30 days shall also be deemed to be an implantable device;

## Examples from the MDCG guidance

The guidance lists these examples under rule 20 (MDCG 2021-24 Rev.1). It is not legally binding, and the class always depends on the intended purpose of the device (Annex VIII, Section 3.1).

### Class IIa

- Inhalers for nicotine replacement therapy (nicotine not included)

  MDCG 2021-24 Rev.1, 4.2, Rule 20, p. 56

### Class IIb

- Nebulisers (not pre-charged with a specific medicinal product) where the failure to deliver the appropriate dosage characteristics could be hazardous

  MDCG 2021-24 Rev.1, 4.2, Rule 20, p. 56

## Classes and Normiq roadmaps

Rule 20 assigns: Class IIa, Class IIb. For each, the Normiq roadmap on every market where Annex VIII applies.

### Class IIa

- [European Union 15 phases · 66 steps · estimated duration 240 days See the roadmap →](https://normiq.app/en/roadmap/eu/class-iia)
- [Switzerland 16 phases · 74 steps · estimated duration 120 days See the roadmap →](https://normiq.app/en/roadmap/switzerland/class-iia)
- [European Union and Switzerland 17 phases · 82 steps · estimated duration 300 days See the roadmap →](https://normiq.app/en/roadmap/eu-switzerland/class-iia)

### Class IIb

- [European Union 15 phases · 68 steps · estimated duration 360 days See the roadmap →](https://normiq.app/en/roadmap/eu/class-iib)
- [Switzerland 16 phases · 77 steps · estimated duration 180 days See the roadmap →](https://normiq.app/en/roadmap/switzerland/class-iib)
- [European Union and Switzerland 17 phases · 85 steps · estimated duration 420 days See the roadmap →](https://normiq.app/en/roadmap/eu-switzerland/class-iib)

## The same rule in Switzerland

> Devices shall be divided into classes I, IIa, IIb and III, taking into account the intended purpose of the devices and their inherent risks. This classification must comply with the provisions of Annex VIII to EU-MDR, taking account of the implementing acts of the European Commission listed in Annex 5a.

Fedlex’s English translation, which has no legal force: the ordinance is official only in French, German and Italian.

[Art. 15 MedDO](https://www.fedlex.admin.ch/eli/cc/2020/552/en#art_15)

The families of rules, the cross-cutting criteria, Rule 11 and common pitfalls are explained in the guide: [MDR classification: the 22 rules of Annex VIII explained](https://normiq.app/en/guides/classification-mdr-annexe-viii)

## Classify your device

The tool asks the questions of the 22 rules of the MDR, one at a time, and gives the indicative class with the rule and its text.

[Open the classification tool](https://normiq.app/en/classification#outil)

## Official sources

- [MDR, consolidated version of July 19, 2026 (02017R0745-20260719), EUR-Lex](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02017R0745-20260719)
- [MDCG 2021-24 Rev.1, “Guidance on classification of medical devices”, April 2026, p. 56](https://health.ec.europa.eu/document/download/cbb19821-a517-4e13-bf87-fdc6ddd1782e_en?filename=mdcg_2021-24_en.pdf)
